Companies /Healthcare

Macrogenics Inc

NASDAQ: MGNX Biotechnology
$3.55
▼ $0.09 (−2.47%) today
Markets closed · 5:43am ET

MGNX at a Glance

Valuation
Market cap
$231.9M
Profitability
Revenue (TTM)
$175.1M
Profit margin
-8.3%
EPS (TTM)
$-1.64
Price
52-week range
$1 – $5
Street target
$8.00
Earnings
Next report
Nov 11, 2026

Headquartered in Rockville, MD Fiscal year ends December NASDAQ: MGNX macrogenics.com

About MacroGenics

MacroGenics is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company generates its pipeline primarily from proprietary next-generation antibody-based technology platforms, including topoisomerase I inhibitor-based antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). Key pipeline candidates include MGC026 (B7-H3 ADC), MGC028 (ADAM9 ADC), MGC030 (undisclosed target ADC), and lorigerlimab (PD-1 × CTLA-4 bispecific DART molecule). The company maintains strategic collaborations with Incyte, Sanofi, and Gilead Sciences. Following the sale of its manufacturing operations to Bora Pharmaceuticals in July 2026, MacroGenics has transitioned to a fully outsourced manufacturing model with an approximately 140-person workforce focused on pipeline advancement. The company trades on NASDAQ under the ticker MGNX. Updated

MGNX Coverage

Frequently Asked Questions

What does MacroGenics do?

MacroGenics is a clinical-stage biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

What is the MGNX stock price target?

The Wall Street consensus 12-month price target for MGNX is $8.00.